INTRODUCTION

Human epidermal growth factor receptor 2 (HER2) overexpression is observed in approximately 20% of patients with breast cancer, and is associated with a high recurrence rate and poor outcome [1]. Trastuzumab—a humanized monoclonal antibody targeting HER2—has significantly improved clinical outcomes in patients with HER2-positive breast cancer [2,3]. However, only 20% of patients respond to trastuzumab alone [2-4], and hence, predictive biomarkers for trastuzumab should be identified in order to maximize its therapeutic benefit.

Mediation of antibody-dependent cell-mediated cytotoxicity (ADCC), which occurs when the monoclonal antibody bound to tumor cells engages with effector cells via the immunoglobulin (Ig) G fragment C receptor (FcrR) expressed on immune cells, is one of the major mechanisms of action of trastuzumab [5]. Genomic FcrR polymorphisms are likely to affect ADCC, and their potential relationship with the clinical outcome of monoclonal antibody therapy has been suggested in lymphoma and colorectal cancer [6,7], as it influences the affinity of IgG [8,9]. Although several studies have investigated the role of FcrR polymorphisms in the efficacy of trastuzumab-containing therapy in patients with metastatic HER2-positive breast cancer. However, this finding warrants further evaluation in the larger population.

Key Words: Breast neoplasms, ErbB-2 receptor, Trastuzumab, Tumor infiltrating lymphocytes
zumab, the findings remain controversial [10-14].

Moreover, previous studies have shown that lymphocyte infiltration may be correlated with improved survival in several cancer types [15-17]. In early stage breast cancer, a greater tumor-infiltrating lymphocytic density, which is mainly found in triple-negative or HER2-positive breast cancer, has been found to be associated with a better response to cytotoxic chemotherapy or HER2-targeted treatment [18-25].

Thus, we aimed to analyze the predictive relevance of FcR polymorphisms and stromal tumor-infiltrating lymphocyte (sTIL) on the clinical outcome of patients with metastatic HER2-positive breast cancer who received trastuzumab-based chemotherapy.

**METHODS**

**Patients**

Between September 2010 and December 2012, 78 patients with metastatic or recurrent HER2-positive breast cancer, who had previously received or were receiving trastuzumab-containing treatment regimens, were enrolled in the present study for analysis of the FcR3A-158 polymorphism. HER2-positivity was defined by immunohistochemical staining intensity 3+ or 2+/fluorescence in situ hybridization (FISH)-positive. Surgical specimens or biopsy specimens were available for 67 patients (85.9%). As the clinical outcomes could be influenced by the chemotherapy regimens, the study analysis included 56 patients who received the trastuzumab-taxane combination as the first-line treatment for their metastatic or recurrent disease. Although it was not an objective of the original study, we also assessed the sTIL levels in tumor tissues in order to evaluate the potential impact of the level of these cells on clinical outcomes of treatment with the trastuzumab-containing regimen. Data regarding baseline patient characteristics and treatment outcomes were retrospectively obtained by reviewing the patients’ medical records. This study was approved by the Institutional Review Board, Asan Medical Center, Seoul, Korea (approval No. 2009-0267), and all patients provided written informed consent.

**FcR3A-158 polymorphism**

Blood (2 mL) was collected into ethylenediaminetetraacetic acid tubes and genomic DNA was extracted. FcR3A genotyping was performed using the single-step multiplex allele-specific real-time polymerase chain reaction techniques previously described [26].

**Assessment of stromal tumor-infiltrating lymphocyte level**

The sTIL level was retrospectively determined using previously collected formalin-fixed paraffin-embedded tumor tissue acquired from surgery (n = 34) or biopsy (n = 22). Hematoxylin-and-eosin (H&E)-stained slides were reviewed by breast cancer pathologists who were blinded to the treatment and clinical outcomes. The slides were then histopathologically analyzed for sTIL level, which was defined as the percentage of stroma of invasive carcinoma infiltrated by lymphocytes, based on recommendations of the International TILs Working Group 2014 [27]. For correlative analysis between sTIL and clinical outcomes, patients were classified into high and low sTIL groups (> 10% vs. ≤ 10%) based on the percentage of the tumor stroma containing infiltrating lymphocytes.

**Statistical analysis**

Tumor responses were determined according to the revised Response Evaluation Criteria in Solid Tumor version 1.1. Progression-free survival (PFS) was defined as the time from the initiation of trastuzumab-taxane chemotherapy until tumor progression or death from any cause, whichever came first. Overall survival (OS) was estimated as the time between the initiation of the trastuzumab-taxane chemotherapy until death from any cause. Survival outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test. Categorical variables were compared using the chi-square or Fisher exact test, as appropriate. A p-value of < 0.05 was considered statistically significant, and SPSS version 20.0 (IBM SPSS Inc., Armonk, USA) was used for all statistical analyses.

**RESULTS**

**Patient characteristics**

A total of 56 patients included in this analysis received first-line trastuzumab-taxane therapy between June 2006 and March 2013. The median age was 55 years (range, 36–76 years), and all patients had HER2-positive invasive ductal carcinoma. Tumor specimens were found to be positive for the hormone receptor in 33 patients (58.9%), while metastatic disease was initially observed in 19 patients (33.9%). Adjuvant chemotherapy was previously provided to 32 patients (57.1%) and adjuvant trastuzumab after curative surgical resection was administered to nine patients (16.1%). The characteristics of the study population are summarized in Table 1. Overall, the median PFS and OS were 20.0 months (95% confidence interval [CI], 15.0–25.0) and 70.0 months (95% CI, 42.6–97.4), respectively, over a median follow-up duration of 57.0 months (95% CI, 37.4–76.6). A summary of subsequent targeted therapy after progression during treatment with trastuzumab is provided in Supplementary Tables 1 and 2 (available online).
Correlative analysis for FcrR3A-158 polymorphism

Twenty-three patients (41.1%) were homozygous for the FcrR3A-158 phenylalanine allele (F/F), 23 patients (41.1%) were heterozygous carriers (F/V), and 10 (17.9%) patients were homozygous for the 158 valine allele (V/V). The median PFS and OS were 12.0 months (95% CI, 5.4–18.5) and 46.5 months (95% CI, 24.2–68.7), respectively, in the V/V group, and 22.1 months (95% CI, 12.9–31.3) and 55.1 months (95% CI, 29.0–81.0), respectively, in the F/V group. In the F/F group, the median PFS was 22.9 months (95% CI, 19.5–26.4), and the median OS was 122 months (95% CI, not assessable). The PFS and OS did not differ significantly according to the FcrR3A polymorphism (p = 0.32, and p = 0.12, respectively) (Figure 1).

Correlative analysis for stromal tumor-infiltrating lymphocyte

Forty-four patients (78.6%) and 12 patients (21.4%) were assigned to the low and high sTIL groups, respectively. There were no significant differences in age (p = 0.93), histologic grade (p = 0.87), hormone receptor status (p = 0.42), metastatic disease setting (p = 0.46), lymph node involvement (p = 0.13), previous adjuvant chemotherapy (p = 0.41), and previous adjuvant trastuzumab (p = 0.41) (Table 2).

Table 1. Baseline characteristics according to the stromal tumor-infiltrating lymphocyte level

| Characteristic                | Total (n=56) | sTIL ≤ 10% (n=44) | sTIL > 10% (n=12) | p-value |
|------------------------------|-------------|------------------|------------------|---------|
| Age (yr)*                    | 55 (36–76)  | 54 (36–76)       | 57 (47–68)       | 0.03    |
| Hormone receptor             |             |                  |                  | 0.42    |
| Positive                     | 33 (58.9)   | 29 (65.9)        | 4 (33.3)         |         |
| Negative                     | 23 (41.1)   | 15 (34.1)        | 8 (66.7)         |         |
| Histologic grade             |             |                  |                  | 0.87    |
| 1–2                          | 31 (55.4)   | 25 (56.8)        | 6 (50.0)         |         |
| 3                            | 14 (25.0)   | 11 (25.0)        | 3 (25.0)         |         |
| Not available                | 11 (19.6)   | 8 (18.2)         | 3 (25.0)         |         |
| Nuclear grade (n=45)         |             |                  |                  | 1.00    |
| 1–2                          | 25 (44.6)   | 20 (45.5)        | 5 (41.7)         |         |
| 3                            | 20 (35.7)   | 16 (36.4)        | 4 (33.3)         |         |
| Not available                | 11 (19.6)   | 8 (18.2)         | 3 (25.0)         |         |
| Disease setting              |             |                  |                  | 0.46    |
| Recurrent                    | 37 (66.0)   | 28 (63.6)        | 9 (75.0)         |         |
| Initially metastatic         | 19 (33.9)   | 16 (36.4)        | 3 (25.0)         |         |
| Metastasis site              |             |                  |                  |         |
| Bone                         | 23 (41.1)   | 20 (45.5)        | 3 (25.0)         | 0.20    |
| Lung                         | 17 (30.4)   | 14 (31.8)        | 3 (25.0)         | 0.66    |
| Liver                        | 11 (19.6)   | 9 (20.5)         | 2 (16.7)         | 0.09    |
| Lymph node involvement       |             |                  |                  | 0.13    |
| Yes                          | 14 (25.0)   | 9 (20.5)         | 5 (41.7)         |         |
| No                           | 42 (75.0)   | 35 (79.5)        | 7 (58.3)         |         |
| Previous adjuvant chemotherapy|            |                  |                  | 0.41    |
| Yes                          | 32 (57.1)   | 24 (54.5)        | 8 (66.7)         |         |
| No                           | 14 (25.0)   | 20 (45.5)        | 4 (33.3)         |         |
| Previous adjuvant trastuzumab|            |                  |                  | 0.41    |
| Yes                          | 9 (16.1)    | 8 (18.2)         | 1 (8.3)          |         |
| No                           | 47 (83.9)   | 36 (81.8)        | 11 (91.7)        |         |

sTIL = stromal tumor-infiltrating lymphocyte.
*Median (range).

Table 2. Response rate according to the stromal tumor-infiltrating lymphocyte level

| Response type                  | sTIL ≤ 10% (n=44) | sTIL > 10% (n=12) | p-value |
|--------------------------------|------------------|------------------|---------|
| Complete or partial response   | 35 (83.3)        | 12 (100)         | 0.13    |
| Stable or progressive disease  | 7 (16.7)         | 0                |         |

sTIL = stromal tumor-infiltrating lymphocyte.
*Among the 44 patients with the level of sTIL ≤ 10%, 2 patients did not have any measurable lesions.

---

Figure 1. Survival outcomes according to the presence of FcrR3A polymorphisms. Both progression-free survival (A) and overall survival (B) did not differ between the F/F, F/V, and V/V group with p-value of 0.32 and 0.12, respectively. F/F = phenylalanine/phenylalanine; F/V = phenylalanine/valine; V/V = valine/valine.
ic sites ($p > 0.05$), previous adjuvant chemotherapy ($p = 0.41$), or subsequent targeted therapies between the two groups ($p = 0.98$) (Table 1 and Supplementary Table 1). The median PFS in the high sTIL group (28.4 months; 95% CI, 21.7–35.0) was significantly longer than that in the low sTIL group (16.8 months; 95% CI, 11.1–22.6; $p = 0.03$) (Figure 2). There was no significant difference between the two groups in OS, with a median of 56.9 months (95% CI, 27.3–86.5) in the low sTIL group and 75.9 months (95% CI, 22.8–129.0; $p = 0.58$). Among the 54 patients with measurable disease, the objective response rates were 83.3% (35/42) in the low sTIL group and 100% (12/12) in the high sTIL group (Table 2). Although there was a trend toward better response rates in the high sTIL group, this was not statistically significant ($p = 0.13$).

**DISCUSSION**

Our findings suggest that sTIL level might be a potential predictive marker in patients with metastatic HER2-positive breast cancer treated with trastuzumab-based therapeutic regimens. However, the FcR3A-158 polymorphism did not appear to be associated with clinical outcomes in patients receiving trastuzumab-based therapy.

In the present study there was a significant association between high sTIL levels and longer PFS in comparison to low sTIL levels (28.4 months vs. 16.8 months, $p = 0.03$) among the 56 patients with metastatic HER2-positive breast cancer who received first-line trastuzumab-taxane chemotherapy. Moreover, the objective response rates of the high sTIL group tended to be higher than those of the low sTIL group (100% vs. 83.3%), although the difference was not statistically significant ($p = 0.13$). While there was no relationship between the sTIL level and OS, this finding might be in part the result of the effects of subsequent treatment after the failure of trastuzumab-taxane therapy, or the small sample size.

The findings of the current study are consistent with the results of previous studies largely performed for early stage breast cancer. In particular, previous retrospective studies on patients with early stage HER2-positive breast cancer who received adjuvant trastuzumab therapy indicated that higher sTIL levels were significantly associated with decreased recurrence rates [22,23]. Similar findings were observed in a subanalysis of clinical trials in the neoadjuvant setting [24,25,28]. A previous study based on two large-scale prospective studies—the GeparQuattro and the NeoALTTO trials—concluded that a better pathologic complete response rate was associated with high sTIL levels [25,28]. Despite the considerable amount of data on early breast cancer in general, only a few reports to date have described the role of sTILs in advanced breast cancer. Recently, a post hoc analysis of the CLEOPATRA study compared pertuzumab-trastuzumab-docetaxel therapy with placebo-trastuzumab-docetaxel therapy in advanced HER2-positive breast cancer [29]. In the study, in which the
sTIL count was evaluated as a continuous variable, higher sTIL levels were significantly associated with improved OS. These findings, in concert with those of the present study, indicate that antitumor immunity may have an impact on the treatment outcomes of advanced stage disease as well as early stage disease.

With regard to the FcrR3A polymorphism, the current study did not show any correlation either with PFS or OS in patients with metastatic HER2-positive breast cancer receiving trastuzumab-based therapy. Although several previous studies have assessed the prognostic significance of FcrR gene polymorphisms in patients with HER2-positive breast cancer treated with trastuzumab, the results have been inconsistent to date [10, 11, 30]. In a previous retrospective report that included 54 patients with metastatic HER2-amplified breast cancer who received trastuzumab-taxane therapy, both the FcrR3A-158 V/V genotype and FcrR2A-131 H/H genotype were found to be independently associated with a better objective response rate and PFS [10]. A subsequent study also reported that the FcrR2A-131 H/H genotype was significantly associated with better clinical outcomes in patients with both early and metastatic breast cancer [11]; however, the FcrR3A-158 V/V genotype was not correlated with treatment outcome. Furthermore, an analysis of a large patient population (1,286 patients with early stage breast cancer and 53 with metastatic breast cancer) indicated no significant correlation between the FcrR3A or FcrR2A genotypes and the survival outcomes with trastuzumab-based therapy [30].

Evaluation of the predictive ability of sTIL levels in metastatic disease, a topic that has received little investigation in contrast to early breast cancer, is a salient feature of the present study. However, our analysis had several limitations of note. First, this study was performed retrospectively in a small number of patients, and hence, there may be an inherent selection bias in the study population. This factor might explain why patients enrolled in this study showed longer PFS and OS than previously observed. Second, the cutoff point for classifying high sTIL level (> 10%) was somewhat arbitrarily determined, as there is currently no available global standard.

In conclusion, the sTIL level may represent a potential predictive biomarker of trastuzumab-based therapy in patients with advanced HER2-positive breast cancer. However, no significant correlation was observed between the FcrR3A polymorphism and clinical outcome. Further investigations should aim to understand the immune microenvironment of HER2-positive breast cancer and standardize the analysis method and clinically relevant cutoff value for categorizing the sTIL status.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

REFERENCES

1. Konceny GE, Meng YG, Untch M, Wang HI, Bauerfeind I, Epstein M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004;10:1706-16.
2. Romond E, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
4. Vogel CL, Cobleigh MA, Tripathy D, Gathan JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
5. Clynnes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6:443-6.
6. Kim DH, Jung HD, Kim JG, Lee JI, Yang DH, Park YH, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006;108:2720-5.
7. Bibeau F, Lopez-Cazes E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, et al. Impact of FcgammaRIIa-Fc gammaRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27:1122-9.
8. Koene HR, Kleijer M, Algra J, Roos D, van der Borne AE, de Haas M. FcgammaRIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcgammaRIIIa, independently of the FcgammaRIIIa-48L/R/H phenotype. Blood 1997;90:1109-14.
9. Parren PW, Warmerdam PA, Boeffe J, Arts J, Westerdaal NA, Vlug A, et al. On the interaction of IgG subclasses with the low affinity Fc gamma RIa (CD32) on human monocytes, neutrophils, and platelets: analysis of a functional polymorphism to human IgG2. J Clin Invest 1992;90:1537-46.
10. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-96.
11. Tamura K, Shimizu C, Hongo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, et al. FcgammaRIIA and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 2011;22:1302-7.
12. Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, et al. ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. Oncology 2012;83:218-27.
al. Association studies of Fcgamma receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831. Cancer Immunol Res 2014;2:962-9.

14. Boero S, Morabito A, Baneli B, Cardinale B, Dozin B, Lunardi G, et al. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcgammaRIIA/FcgammaRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. J Transl Med 2015;13:324.

15. Pagès E, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Binde G, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009;27:5944-51.

16. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.

17. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001;61:5132-6.

18. Denkert C, Lobh S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28:105-13.

19. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011;29:1949-55.

20. Loi S, Sirtaine N, Pette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013;31:860-7.

21. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014;32:2959-66.

22. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014;25:1544-50.

23. Lee HJ, Kim JY, Park IA, Song IH, Yu JH, Ahn JH, et al. Prognostic significance of tumor-infiltrating lymphocytes and the tertiary lymphoid structures in HER2-positive breast cancer treated with adjuvant trastuzumab. Am J Clin Pathol 2015;144:278-88.

24. Liu S, Duan X, Xu L, Xin L, Cheng Y, Liu Q, et al. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy. Breast Cancer Res Treat 2015;154:239-49.

25. Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO Trial. JAMA Oncol 2015;1:448-54.

26. Dall'Ozzo S, Andres C, Bardos P, Watier H, Thibault G. Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in real-time multiplex allele-specific PCR. J Immunol Methods 2003;277:185-92.

27. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015;26:259-71.

28. Ingold Heppner B, Untch M, Denkert C, Pfitzenner BM, Lederer B, Schmitt M, et al. Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer. Clin Cancer Res 2016;22:5747-54.

29. Luem SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol 2017;18:52-62.

30. Huvritz SA, Betting DJ, Stern HM, Quinaux E, Stinson I, Seshagiri S, et al. Analysis of Fcgamma receptor IIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res 2012;18:3478-86.